We find CMV+ patients with MM have clinically favorable hematological markers before treatment, namely reduced NLR, fewer Treg cells, increased T cell clonality and cytotoxicity, and a distinct CD8+ T cell transcriptomic profile, with upregulation of pathways including TCR and IFNγ-mediated signaling. This evidence concerns the gene CD8A and Miyoshi myopathy.